<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113331</url>
  </required_header>
  <id_info>
    <org_study_id>CRI 88413</org_study_id>
    <nct_id>NCT03113331</nct_id>
  </id_info>
  <brief_title>The 3D Cohort Study (Design, Develop, Discover)</brief_title>
  <acronym>3D</acronym>
  <official_title>3D Cohort Study: The Integrated Research Network in Perinatology of Quebec and Eastern Ontario</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 3D Cohort Study (Design, Develop, Discover) was established to help bridge knowledge gaps
      about the links between various adverse exposures during pregnancy with birth outcomes and
      later health outcomes in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the 3D study is to create a large pregnancy and birth cohort, allowing
      for the assessment of the effects of combined prenatal exposure on both birth outcomes and
      longer-term infant and child health. The specific objectives are to:

        1. Determine the effects of pre- and post-natal exposures to environmental contaminants,
           nutritional factors and psychosocial stress on pregnancy and neurodevelopmental
           outcomes;

        2. Assess the contribution of social, genetic, epigenetic, nutritional and environmental
           factors to the etiology and outcomes of intrauterine growth restriction (IUGR) and
           preterm birth; and

        3. Assess the effects of assisted reproductive technologies (ART) on indicators of
           epigenetic modifications, and the relationship between such epigenetic changes and
           infant neurodevelopmental, cardiovascular, and metabolic outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 25, 2010</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intrauterine growth restriction</measure>
    <time_frame>At delivery</time_frame>
    <description>Birth weight smaller than 10th percentile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>At delivery</time_frame>
    <description>Delivery before 37 weeks of gestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurodevelopment - Bayley</measure>
    <time_frame>When infants are 2 years old</time_frame>
    <description>Neurodevelopmental assessment of the infant. Test used : Bayley Scales of Infant and Toddler Development (BSID‐III; cognitive scale and motor scale combined). This test was done on 1520 children.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurodevelopment - ABAS</measure>
    <time_frame>When infants are 2 years old</time_frame>
    <description>Neurodevelopmental assessment of the infant. Test used : Bayley Adaptive Behaviour Questionnaire (ABAS‐II). This test was done on 1520 children.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurodevelopment - Sensory Profile</measure>
    <time_frame>When infants are 2 years old</time_frame>
    <description>Neurodevelopmental assessment of the infant. Test used : Sensory Profile questionnaire. This test was done on 1520 children.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurodevelopment - MacArthur-Bates</measure>
    <time_frame>When infants are 2 years old</time_frame>
    <description>Neurodevelopmental assessment of the infant. Test used : MacArthur Communicative Development Inventories (CDI; French, English, Spanish and/or Mandarin). This test was done on 1520 children.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurodevelopment - M-CHAT</measure>
    <time_frame>When infants are 2 years old</time_frame>
    <description>Neurodevelopmental assessment of the infant. Test used : Modified Checklist of Autism in Toddlers (M‐CHAT). This test was done on 1520 children.</description>
  </primary_outcome>
  <enrollment type="Actual">2366</enrollment>
  <condition>Pregnancy Outcome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal: blood, urine, vaginal secretions, nails, cord blood, placenta, hair, saliva Infant:
      hair, meconium, blood, urine, saliva Father: Blood, urine, saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The 3D Cohort Study is structured around a triadic (mother‐partner‐child) framework. The
        cohort comprises 2366 women recruited in the first trimester of pregnancy (8-14 weeks) who
        were planning to deliver in a collaborating hospital in the province of Quebec. Women and
        their partners were recruited between May 25, 2010 and August 30, 2012 at one of nine study
        centres during routine first‐trimester prenatal visits to study hospitals and infertility
        clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to communicate in French or English

        Exclusion Criteria:

          -  Current intravenous drug use

          -  Severe illnesses or life threatening conditions

          -  Multiple gestation pregnancies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>William D Fraser, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Fraser WD, Shapiro GD, Audibert F, Dubois L, Pasquier JC, Julien P, Bérard A, Muckle G, Trasler J, Tremblay RE, Abenhaim H, Welt M, Bédard MJ, Bissonnette F, Bujold E, Gagnon R, Michaud JL, Girard I, Moutquin JM, Marc I, Monnier P, Séguin JR, Luo ZC; 3D Study Group. 3D Cohort Study: The Integrated Research Network in Perinatology of Quebec and Eastern Ontario. Paediatr Perinat Epidemiol. 2016 Nov;30(6):623-632. doi: 10.1111/ppe.12320. Epub 2016 Oct 25.</citation>
    <PMID>27781295</PMID>
  </results_reference>
  <results_reference>
    <citation>Morisset AS, Dubois L, Colapinto CK, Luo ZC, Fraser WD. Prepregnancy Body Mass Index as a Significant Predictor of Total Gestational Weight Gain and Birth Weight. Can J Diet Pract Res. 2017 Jun 1;78(2):66-73. doi: 10.3148/cjdpr-2016-035. Epub 2017 Feb 1.</citation>
    <PMID>28145732</PMID>
  </results_reference>
  <results_reference>
    <citation>Balayla J, Sheehy O, Fraser WD, Séguin JR, Trasler J, Monnier P, MacLeod AA, Simard MN, Muckle G, Bérard A. Neurodevelopmental Outcomes After Assisted Reproductive Technologies. Obstet Gynecol. 2017 Feb;129(2):265-272. doi: 10.1097/AOG.0000000000001837.</citation>
    <PMID>28079770</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro GD, Séguin JR, Muckle G, Monnier P, Fraser WD. Previous pregnancy outcomes and subsequent pregnancy anxiety in a Quebec prospective cohort. J Psychosom Obstet Gynaecol. 2017 Jun;38(2):121-132. doi: 10.1080/0167482X.2016.1271979. Epub 2017 Jan 12.</citation>
    <PMID>28079434</PMID>
  </results_reference>
  <results_reference>
    <citation>Lamarre V, Gilbert NL, Rousseau C, Gyorkos TW, Fraser WD. Seroconversion for cytomegalovirus infection in a cohort of pregnant women in Québec, 2010-2013. Epidemiol Infect. 2016 Jun;144(8):1701-9. doi: 10.1017/S0950268815003167. Epub 2015 Dec 21.</citation>
    <PMID>26686548</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>William Fraser</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Intrauterine growth restriction</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Birth defect</keyword>
  <keyword>Infant growth</keyword>
  <keyword>Neurodevelopmental outcomes</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

